Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)’s share price was down 6% during trading on Wednesday . The company traded as low as $14.41 and last traded at $14.52, with a volume of 849,115 shares trading hands. The stock had previously closed at $15.45.

A number of equities analysts have recently commented on LXRX shares. Cowen and Company reissued a “market perform” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, May 3rd. Needham & Company LLC reissued a “buy” rating and issued a $21.00 price target on shares of Lexicon Pharmaceuticals in a research report on Wednesday, May 4th. JPMorgan Chase & Co. reissued a “hold” rating and issued a $16.00 price target on shares of Lexicon Pharmaceuticals in a research report on Thursday, May 5th. Wedbush reissued an “outperform” rating and issued a $28.00 price target on shares of Lexicon Pharmaceuticals in a research report on Friday, May 6th. Finally, Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, May 6th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $20.07.

The firm’s market cap is $1.51 billion. The stock’s 50 day moving average is $15.57 and its 200 day moving average is $13.26.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.04. During the same quarter in the prior year, the company earned ($0.27) earnings per share. The business earned $20.10 million during the quarter, compared to the consensus estimate of $12.36 million. Lexicon Pharmaceuticals’s revenue was up 5186.8% compared to the same quarter last year. On average, equities research analysts forecast that Lexicon Pharmaceuticals Inc. will post ($1.54) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Lexicon Pharmaceuticals stock. Schwab Charles Investment Management Inc. raised its position in Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) by 3.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,093 shares of the biopharmaceutical company’s stock after buying an additional 4,338 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.14% of Lexicon Pharmaceuticals worth $1,985,000 as of its most recent filing with the SEC.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.